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ABSTRACT
We have addressed whether patients’ immune system status after allogeneic stem cell transplantation, assessed
more than 1 year after the procedure, recovers normal function as compared with that of their respective
donors. An additional aim was to compare the status of the immune system between patients receiving
reduced-intensity conditioning regimens and those undergoing myeloablative transplantations. For this pur-
pose, we analyzed not only the different subsets of peripheral blood (PB) lymphocytes, but also circulating
dendritic cell (DC) subpopulations, together with cytokine production by PB T cells, in a series of 38 patients
undergoing allogeneic stem cell transplantation. We compared these patients with their respective HLA-
matched donors by performing a simultaneous patient/donor paired study. Complete bone marrow chimerism
status and normal PB cell counts were demonstrated in all recipients. The most relevant numeric differences
found between patients and donors were related to the distribution of the distinct subsets of PB DCs (CD16
DCs were increased, whereas myeloid and plasmacytoid DC subsets were decreased in the patient group). This
was associated with an increased number of B cells, an inverted CD4/CD8 T-cell ratio, and a decrease in
CD4/CD8 double-positive T cells in the patient group. In addition, a predominance of a T-helper 1 pattern
of cytokine production (interferon  and tumor necrosis factor ) with decreased secretion of T-helper
2–associated cytokines (interleukin 5 and interleukin 10) was also observed at the single-cell level. No
significant differences were found in any of the parameters analyzed between patients receiving reduced-
intensity conditioning regimens and those undergoing myeloablative transplantations.
© 2005 American Society for Blood and Marrow Transplantation
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oNTRODUCTION
Immunologic recovery after allogeneic stem cell
ransplantation (allo-SCT) plays an important role in the
ong-term outcome of patients after transplantation, be-
ause it inﬂuences the occurrence of clinical complica-
ions that account for most late posttransplantation mor-
ality [1]. First, a deﬁcient immune system favors
osttransplantation infectious complications [2] and the
evelopment of secondary neoplasia [3]. Second, it is also
ssociated with a higher relapse rate [4]. s
54Immune recovery during the ﬁrst year after allo-
CT has been extensively studied by different groups
5-10]. After that time point, studies reported in the
iterature are scanty and have mainly focused on the
uantitative and/or qualitative evaluation of T cells
nd B lymphocytes; they have used relatively complex
unctional assays that currently cannot be routinely
erformed in a clinical setting and have used unrelated
ndividuals as a control group [11,12]. The major goal
f this study was to evaluate the status of the immune
ystem at least 1 year after transplantation in a series of
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Compared Immune System in Patients and Donors
B8 patients who had received an HLA-identical sibling
llo-SCT and to compare it with that of their respec-
ive related donors. Our interest was focused on the
umeric and functional analysis not only of the differ-
nt subsets of peripheral blood (PB) lymphocytes, but
lso of circulating dendritic cell (DC) subpopulations.
he results were evaluated simultaneously in a pa-
ient/donor paired study performed only after com-
lete bone marrow chimerism and normal PB cell
ounts were shown in all recipients. An additional goal
f this study was to analyze the status of the immune
ystem in a group of patients receiving a reduced-
ntensity conditioning (RIC) regimen as compared
ith those undergoing conventional myeloablative
ransplantations.
ATERIALS AND METHODS
atients and Donors
From October 1995 to April 2000, 134 patients
nderwent a matched related donor allo-SCT in our
nstitution. At the time the study was designed, 68
ere alive and disease free. Of these, only 38 patients,
ogether with their respective donors, ﬁnally gave
heir written informed consent to participate. The
rotocol was approved by the local ethics committee,
nd the main criteria for eligibility included more than
year from transplantation (median time, 769 days;
ange, 367-1960 days), normal PB cell counts, absence
f infectious diseases in the previous 3 months, and
emonstration of complete bone marrow chimerism
t the time of the study. Complete bone marrow
himerism was conﬁrmed in all recipients by polymer-
se chain reaction (short tandem repeats analysis), as
reviously described [13].
The median age was 42 years (range, 17-67 years)
nd 41 years (range, 17-73 years) in the patient and
onor groups, respectively, whereas the male-female
atio was 20:18 in both groups. Patients’ clinical and
ransplant characteristics are summarized in Table 1.
B samples were simultaneously obtained from both
atients and donors, and information on every param-
ter measured was available in all 38 pairs (there were
o missing data).
mmunophenotypic Analysis of PB DCs
For the immunophenotypic analysis of circulating
Cs and their subsets, ethylenediaminetetraacetic aci-
–anticoagulated PB samples (approximately 2  106
ells per test) were analyzed by direct immunoﬂuores-
ence by using a single 4-color combination of 7
onoclonal antibodies (MAbs) conjugated with ﬂuo-
escein isothiocyanate (FITC), phycoerythrin (PE),
eridinin chlorophyll protein (PerCP), and allophyco-
yanin (APC): CD3/CD14/CD19/CD56-FITC/CD16-
E/HLA-DR-PerCP/CD33-APC. FITC-conjugated s
B & M Teagents were purchased from Cytognos SL
Salamanca, Spain). All other MAbs were from Becton
ickinson Biosciences (San Jose, CA). Preparation of
B samples was performed with a stain-lyse-and-then-
ash technique, as previously described in detail [14].
nformation on stained cells was acquired in 2 sequen-
ial steps in a standard dual-laser FACSCalibur ﬂow
ytometer (Becton Dickinson Biosciences) by using
ellQuest software (Becton Dickinson Biosciences).
irst, 2  104 events per test, corresponding to the
rythrocyte-lysed whole PB sample cellularity, were
ollected. In a second step, information was stored
xclusively for 10 000 HLA-DR/CD3neg/
D14neg/CD19neg/CD56neg (major histocompatibil-
ty complex II/lineageneg) events, included in an elec-
ronic live gate. Paint-A-Gate Pro Software (Becton
ickinson Biosciences) was used for data analysis, as
reviously described in detail [15,16]. DCs were iden-
iﬁed as events that showed intermediate forward and
able 1. Clinical and Transplant-Associated Characteristics of Patients
Variable Value
nderlying hematologic disease
Acute myeloid leukemia 12 (31.5)
Chronic myeloid leukemia 6 (15.8)
Myelodysplastic syndrome 6 (15.8)
Acute lymphocytic leukemia 5 (13.1)
Chronic lymphocytic leukemia 2 (5.2)
Hodgkin disease 2 (5.2)
Aplastic anemia 2 (5.2)
Multiple myeloma 1 (2.6)
Non-Hodgkin lymphoma 1 (2.6)
Congenital sideroblastic anemia 1 (2.6)
ype of conditioning regimen
Myeloablative 20 (52.6)
Reduced intensity 18 (47.3)
BO status
Identical 23 (60.5)
Major incompatibility 7 (18.4)
Minor incompatibility 7 (18.4)
Major and minor incompatibility 1 (2.6)
tem cell source
Bone marrow 4 (10.5)
Peripheral blood (nonmanipulated) 34 (89.4)
ell dose infused
CD34 cells (106/kg body weight) 5.0 (2.3-10.0)
Nucleated cells (108/kg body weight) 7.7 (2.1-20.6)
Total number of T cells infused (1010) 1.6 (0.1-4.1)
evelopment of acute GVHD 16 (42.1)
Grade I 2 (12.5)
Grade II 14 (87.5)
evelopment of chronic GVHD 24 (63.1)
Limited 6 (25)
Extensive 18 (75)
Active; under treatment during the study 9 (23.6)
MV antigenemia or disease 9 (23.6)
CMV antigenemia 8 (21.0)
CMV disease 1 (2.6)
None 29 (76.3)
alues are expressed as the median number of cases (percentage) or
median (range).
MV indicates cytomegalovirus.ide light scatter characteristics (between lymphocytes
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3nd monocytes), strong HLA-DR expression, and lack
f lineage-speciﬁc markers (CD3, CD19, CD56, and
D14). Quantiﬁcation of the overall percentage of
Cs present in each PB sample was performed by
alculating the proportion of HLA-DR/lineageneg
ells stored in the ﬁrst acquisition step, after excluding
ell debris. Absolute counts were obtained by multi-
lying the percentage of DCs obtained by the total
eukocyte count per microliter obtained for that
ample in a Cell-Dyn 4000 hematologic cell counter
Abbott, Santa Clara, CA). Three DC subpopulations
ere identiﬁed by further analysis of PB DCs: CD16
C (CD16/HLA-DR/CD14neg/dim/CD33), my-
loid DC (CD16neg/HLA-DR/CD33), and plas-
acytoid DC (CD16neg/HLA-DR/CD33neg) sub-
opulations [15].
mmunophenotypic Analysis of PB Lymphocytes
For the identiﬁcation and enumeration of differ-
nt subpopulations of PB lymphocytes, 100 L of
thylenediaminetetraacetic acid–anticoagulated PB
er individual sample was stained with the CD45-
PC (Becton Dickinson Biosciences) and Lympho-
ram (Cytognos) reagent kit, which contained the
D8-FITC, CD19-FITC, CD3-PE, CD56-PE, and
D4-PECy5 MAb reagents, by strictly following the
ecommendations of the manufacturer for a stain, lyse,
o-wash procedure. Immediately before data acquisi-
ion, 100 L of FlowCount microbeads (Beckman
oulter, Fullerton, CA) was added to each tube by
everse pipetting. Data acquisition was performed im-
ediately after completion of sample preparation in
FACSCalibur ﬂow cytometer (Becton Dickinson
iosciences). The CellQuest and Paint-A-Gate Pro
Becton Dickinson Biosciences) programs were used
or data acquisition and analysis, respectively. The
ollowing lymphocyte subsets were identiﬁed [17,18]:
cells (CD19), natural killer (NK) cells (CD56,
D3), CD4/CD8 T cells (CD3, CD4, CD8),
D8/CD4 T cells (CD3, CD4, CD8), CD4/
D8 T cells (CD3, CD4, CD8), and CD4/
D8 T cells (CD3, CD4, CD8).
unctional Analysis of Cytokine Production by PB
Cells
Cytokine secretion by PB T cells was analyzed
fter culturing 1000 L of 1:1 (vol/vol) heparin-anti-
oagulated PB diluted 1:1 (vol/vol) in RPMI culture
edium (BioWhittaker, Walkersville, MD) supple-
ented with 2 mmol/L l-glutamine for 4 hours in the
resence of 25 ng/mL of phorbol-12-myristate-13-
cetate (PMA; Sigma, St. Louis, MO) and 1 g/mL
onomycin (Sigma), together with 10 g/mL brefeldin
(Sigma), as described previously in detail [19]. An
nstimulated aliquot of the same sample, also contain-
ng brefeldin A in the absence of PMA and ionomycin, t
56as processed in parallel in an identical way, as a
egative control. After they were cultured, both stim-
lated and unstimulated samples were aliquoted into 3
ifferent tubes (100 L each), stained with CD8-
ITC (Becton Dickinson Biosciences) and CD3 PerCP-
y 5.5 (Becton Dickinson Biosciences), and
equentially ﬁxed, permeabilized, and stained for in-
racellular cytokines by using the Fix&Perm reagent
it (Caltag, San Francisco, CA) according to the rec-
mmendations of the manufacturer. The speciﬁcity
nd source of the anti-cytokine MAb used was as
ollows: anti–interferon (IFN)––PE, anti–interleukin
IL)–5–PE, anti–IL-4–APC, anti–IL-2, and anti–IL-
0 were all purchased from Pharmingen (San Diego,
A), and anti–tumor necrosis factor (TNF)––APC
as purchased from Becton Dickinson Biosciences.
sotype-matched mouse MAb reagents conjugated
ith ﬂuorochromes not directed against human anti-
ens were used as negative controls. Data acquisition
as performed on a FACSCalibur ﬂow cytometer
Becton Dickinson Biosciences) by using CellQuest
oftware (Becton Dickinson Biosciences). For data
nalysis, the Paint-A-Gate Pro software program
Becton Dickinson Biosciences) was used. Evaluation
f cytokine production was based on the percentage of
ositive cells within each T-cell subset (CD3/CD8
nd CD3/CD8; the latter is referred to as the
D4/CD8neg subset from now on) from the PMA
lus ionomycin–stimulated samples, after subtracting
he percentage of cells from the corresponding un-
timulated sample’s aliquot showing reactivity for the
ame cytokine (always 1%).
tatistical Analyses
All statistical analyses were performed with SPSS
oftware (SPSS Inc., Chicago, IL). For each variable
nder study, percentages, mean and SEM, or median
nd range were calculated. To assess the statistical
igniﬁcance of the differences observed between groups,
he 2 test was used for categorical variables. For
ontinuous variables, normality was assessed by the
olmogorov-Smirnov test. When the assumption of
ormality was met, differences between groups were
ested by the Student t test or analysis of variance.
ariables that did not show a normal distribution were
ested by using nonparametric analysis (Kruskal-
allis test). Pearson’s correlation coefﬁcient was cal-
ulated between the patient and donor immune sys-
em parameters. Finally, to evaluate whether some
linical characteristics inﬂuenced the immune system
tatus of patients, we performed an initial survey and
elected the following relevant variables: patient age,
ime from transplantation to study, type of condition-
ng regimen, absolute number of T cells infused, pres-
nce of cytomegalovirus antigenemia or disease after
ransplantation, previous acute graft-versus-host dis-
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Compared Immune System in Patients and Donors
Base (GVHD), and presence of chronic GVHD under
reatment at the time of the study. These variables
ere included in a general linear model analysis to
ssess their inﬂuence on each patient’s immune system
arameters.
ESULTS
istribution of PB DCs
Although the total numbers of circulating DCs in
atients who underwent sibling allo-SCT were not
igniﬁcantly different from those of their respective
elated donors (Table 2), interesting differences
merged with analysis of DC subsets. Thus, patients
ho had more CD16 DCs (P 	 .01), whereas both
yeloid and plasmacytoid DC subsets were signiﬁ-
antly decreased (P 	 .03 and P 	 .001, respectively)
s compared with their respective sibling donors (Ta-
le 2). A signiﬁcant correlation was observed between
atients’ and donors’ total DC counts (P 	 .009; r2 	
.410) and CD16 DC (P 	 .016; r2 	 0.390) and
lasmacytoid DC (P 	 .018; r2 	 0.445) subsets.
istribution of PB NK, B-Cell, and T-Cell
ubpopulations
Patients and their respective donors had similar
umbers of circulating PB NK cells (Table 3). As for
Cs, a signiﬁcant correlation was found between the
umber of NK cells in the patient and donor PB
amples (P 	 .01; r2 	 0.4). This was the only clinical
nd transplant-associated parameter that inﬂuenced
ong-term NK cell numbers in the patient group.
onversely, at the time of this study, B-cell numbers
able 3. Distribution of PB NK Cell, B-Cell, and T-Cell Subsets in th
Lymphocyte Subset Patient
otal lymphocytes (106/L) 2220  3
K cells (106/L) 250  6
cells (106/L) 453  5
otal T cells (106/L) 1516  2
D4 T cells (106/L) 714  1
D8 T cells (106/L) 701  1
D4/CD8 T cells (106/L) 12  2
D4neg/CD8neg T cells (106/L) 88  1
S indicates not statistically signiﬁcant; NK, natural killer.
able 2. Distribution of Peripheral Blood Dendritic Cell Numbers in
he Patient and Donor Groups
Parameter Patients Donors P Value
otal DC count (106/L) 59.0  10 52.3  6 NS
D16 DCs (106/L) 46.3  10 33.7  6 .01
yeloid DCs (106/L) 6.9  1.4 8.9  1.4 .03
lasmacytoid DCs (106/L) 6.2  1.4 10.6  2 .001
S indicates not statistically signiﬁcant; DCs, dendritic cells.
alues are expressed as mean 
 2 SE.alues are expressed as mean 
 2 SE.
B & M Tere signiﬁcantly higher in the patient group as com-
ared with the donor group (Table 3), although serum
mmunoglobulin G and immunoglobulin A levels
ere still signiﬁcantly decreased at this time point
data not shown).
Regarding T cells, our results showed an inversion
f the CD4/CD8 T-cell ratio that was due to both
ecreased CD4 T-cell numbers and increased CD8
-lymphocyte counts, in association with fewer double-
ositive CD4/CD8 T cells in the patient group. In
ontrast, similar numbers of the double-negative
CD4neg and CD8neg) T-cell subset were found in
he patient group and their respective sibling donors
Table 3).
ytokine Production by Stimulated T Cells
Table 4 shows the results obtained through the
nalysis of cytokine production by the 2 major T-cell
ubsets (CD8/CD4neg and CD8neg/CD4 T cells)
pon stimulation with PMA and ionomycin. T cells
rom patients displayed an increased production of
NF- and IFN- together with a decreased produc-
ion of IL-5, IL-2, and IL-10, as compared with their
espective sibling donors.
nfluence of Clinical Characteristics
Among the variables included in the general linear
odel analysis, the presence of chronic GVHD was
he one with more inﬂuence on the immune system. A
ower number of PB B cells (309 
 42 B cells per
icroliter versus 543 
 48 B cells per microliter; P 	
03), and lower numbers of IL-4–secreting (0.89
 0.2
ersus 1.48 
 0.2; P 	 .01), IL-5–secreting (2.69 

.4 versus 4.51 
 0.5; P 	 .01), and IL-10–secreting
0.64 
 0.2 versus 1.47 
 0.3; P 	 .01) CD4 T cells
ere found in this subgroup when compared to pa-
ients without this complication. The total number of
cells infused directly correlated with the absolute
umber of PB T cells (P  .001; r2 	 0.639) and with
B CD4/CD8neg (P 	 .001; r2 	 0.54) and CD4neg/
D8 (P 	 .02; r2 	 0.42) T cells. Patient age inﬂu-
nced plasmacytoid DC numbers (P 	 .03), with
ower counts in elderly patients. Previous acute
t and Donor Groups
Donors P Value
1968  216 NS
272  44 NS
249  36 <.001
1447  184 NS
909  104 .027
445  70 .004
19  4 .005
72  14 NSe Patien
s
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3VHD or cytomegalovirus antigenemia/disease and
ime from transplantation to study did not show any
ffect. Finally, there was no difference between pa-
ients undergoing RIC and those undergoing myeloa-
lative transplantation in any of the immune system
arameters analyzed (Table 5).
ISCUSSION
Recovery of the immune system after an allo-SCT
s known to play a key role in the long-term outcome.
n many studies abnormalities have been identiﬁed,
ostly regarding CD4 T-cell recovery, but also in-
olving other T-cell and B-cell populations [11,12,
0,21]. However, some of them have not been con-
rmed or remain controversial. One major reason that
ould contribute to explaining these apparent discrep-
ncies could be related to the different individuals and
ontrol groups used in each study. To overcome this
imitation, in this descriptive study, we performed a
ultiparametric analysis of the normal distribution
nd functionality of different subsets of PB DCs, NK
ells, and B and T cells in a group of 38 patients more
han 1 year after sibling allo-SCT, using their respective
ibling donors as controls. In this setting, when complete
onor chimerism has been achieved in patients, the sib-
ing donors studied simultaneously are the ideal control
roup.
Our results showed normal absolute DC and lym-
hocyte counts in the patient group compared with
heir donors at the time of study. These data are in
ccordance with previous reports that showed recov-
ry of DC and lymphocyte counts up to the normal
ange within the ﬁrst year after transplantation
1,22,23]. Nevertheless, a more detailed analysis of
hese cells showed some differences between groups.
ccordingly, patients displayed a different DC distri-
ution compared with their donors, with an increased
umber of CD16 DCs and decreased counts of both
able 4. Cytokine Production by PMA Plus Ionomycin–Stimulated PB
Cytokine T-Cell Subset P
TNF- cells CD8
CD4
IFN- cells CD8
CD4
IL-4 cells CD8
CD4
IL-5 cells CD8
CD4
IL-2 cells CD8
CD4
IL-10 cells CD8
CD4
S indicates not statistically signiﬁcant.
alues are expressed as mean 
 2 SE.yeloid and plasmacytoid DC subsets. CD16 DCs V
58onstitute a poorly understood subset of PB cells, and
lthough the origin—DC versus monocytes [24] —has
een a matter of extensive debate, recent studies favor
DC origin because these cells exhibit phenotypic and
unctional characteristics different from those ob-
erved in PB monocytes acting as potent antigen-
resenting cells for naive T lymphocytes [15,25].
The role of this cell subset in the posttransplan-
ation setting has not been previously evaluated, al-
hough some studies suggest that in several situations
ith enhanced tissue damage, such as sepsis [26,27] or
rteriosclerosis [28], CD16 DCs are increased. Re-
from Allo-SCT Patients and Donors
Group Donor Group P Value
7 30  6 .001
6 25  5 .003
6 46  6 <.001
5 24  3 <.001
0.2 1.1  0.2 NS
0.2 1.5  0.2 NS
0.6 3.0  0.8 NS
0.6 4.0  0.8 .007
3 22  4 .013
4 48  4 .026
0.2 0.9  0.2 .028
0.1 1.7  0.2 .03
able 5. Compared Immune System Status in Patients Receiving RIC
ersus Myeloablative Transplants
Parameter
RIC
(n  18)
Myeloablative
(n  20)
otal DCs (106/L) 62  18 51  12
D16 DCs (106/L) 50  16 37  10
yeloid DCs (106/L) 7.7  1.6 6.6  2.2
lasmacytoid DCs (106/L) 5.7  1.8 6.5  2
K cells (106/L) 269  85 222  74
-cells (106/L) 466  96 395  55
otal T cells (106/L) 1637  201 1431  156
D4 T cells (106/L) 774  114 655  74
D8 T cells (106/L) 767  115 662  95
D4/CD8 T cells (106/L) 12  4 13  4
D4neg/CD8neg T cells (106/L) 83  24 99  23
TNF- cells CD8 cells 45  10 44  12
TNF- cells CD4 cells 33  10 37  8
IFN- cells CD8 cells 66  10 69  8
IFN- cells CD4 cells 34  6 38  8
IL-4 cells CD8 cells 0.9  0.2 0.8  0.2
IL-4 cells CD4 cells 1.3  0.4 1.3  0.3
IL-5 cells CD8 cells 2.1  0.5 2.1  0.4
IL-5 cells CD4 cells 4.0  1.4 4.4  1.0
IL-2 cells CD8 cells 12  3 19  4
IL-2 cells CD4 cells 39  6 45  6
IL-10 cells CD8 cells 0.5  0.2 0.5  0.2
IL-10 cells CD4 cells 1.3  0.4 1.2  0.4
o signiﬁcant differences were found between groups for any pa-
rameter measured.T-Cells
atient
44 
34 
68 
36 
0.8 
1.3 
2.3 
3.1 
16 
43 
0.6 
1.3 alues are expressed as mean 
 2 SE.
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Compared Immune System in Patients and Donors
Barding other DC subsets, plasmacytoid DCs were
iminished in patients as compared with their respec-
ive donors. In our study, patient age inﬂuenced the
ecovery of this DC subset, with lower counts in
lderly patients. Previous reports in healthy subjects
ave shown a progressive decline in plasmacytoid DCs
ith age [29]. This decrease may be related to the
iminished tolerogenic ability displayed by elderly pa-
ients who had undergone transplantation. However,
his DC subset has been reported to be diminished in
he long term after the procedure, also in younger
atients [22,23,30].
From the 3 major subsets of PB lymphocytes, B
ells showed the most differences between patients
nd donors, with increased B cell numbers in the
ormer group. Previous studies on B-cell kinetics after
llo-SCT are consistent with our data, showing that B
ells are usually increased up to 2 years after trans-
lantation, with a progressive decrease toward normal
alues subsequently [1]. This may resemble normal
ntogenic B-cell development [31]. Regarding NK
ells, normal counts were found in the long term after
llo-SCT, in accordance with previous studies show-
ng that these cells usually reach values within the
ormal range early after transplantation [32,33].
Regarding T cells, an inversion of the CD4/CD8
atio was observed in our series. This was due to both
signiﬁcant decrease in CD4 T cells and an increase
n CD8 T lymphocytes. Inversion of the CD4/CD8
-cell ratio can be ascertained even up to 5 years after
he allo-SCT, mainly because of a defective CD4
-cell reconstitution [2,11,12]. In this study, we found
urther evidence that reconstitution of T cells may be
irectly related to the number of donor T cells infused
34], because the number of T cells in the patient in
he long term were correlated with the number of T
ells infused. In addition to the abnormalities ob-
erved in the 2 major CD4/CD8neg and CD4neg/
D8 T-cell subsets, our data showed that double-
ositive (CD4/CD8) T cells were signiﬁcantly
ecreased in the patient group. These cells have
carcely been previously assessed in the post–allo-
CT setting [31] and represent a subpopulation of
ifferentiated effector memory cells with antitumor
nd antiviral functions [2,12,35] that was found to be
ncreased in patients early after transplantation, in
emporal association with some viral infections [36] or
ust resembling normal ontogeny [31]. Nevertheless,
n our study, we found a decrease in this subset that
ay be related to the absence in all our patients of
iral infections, at least in the 3 months before the
tudy and/or the later posttransplantation time point
hen the assessment was performed.
Although ﬂow cytometric assessment of intracellular
ytokine production has been recommended (National
ommittee for Clinical Laboratory Standards–approved
uidelines) to evaluate T-cell functionality [19,37,38],
B & M To the best of our knowledge this is the ﬁrst study in
hich, in the long-term setting after allo-SCT, cyto-
ine production by stimulated T-cell subsets has been
peciﬁcally investigated at the cytoplasmic level on a
ingle-cell basis. Our results indicated that, as com-
ared with their respective donors, patients exhibited
n increased production of TNF- and IFN- asso-
iated with decreased numbers of IL-5– and IL-10–
ecreting T cells. These results, together with the
ncreased CD8 T-cell numbers in PB, support the
otion that at the study time point, a predominance of
T-helper (Th)1 T-cell response exists in patients
ndergoing allo-SCT in comparison to their respec-
ive donors. Even though a Th1 pattern of cytokine
roduction has been associated with the presence of
cute GVHD in the classic model proposed by Antin
nd Ferrara [39], a history of acute GVHD did not
nﬂuence cytokine production in our study, performed
ore than 1 year after transplantation. Conversely,
atients with chronic GVHD under immunosuppres-
ive treatment displayed a signiﬁcantly decreased pro-
uction of IL-5 and IL-10 compared with the other
atients. These cytokines are involved in a Th2 re-
ponse, and an increase—instead of a decrease—in
heir numbers would be expected in chronic GVHD
atients,[40] although some authors have found dis-
ordant results on this matter [41-43]. Unfortunately,
ecause patients with chronic GVHD were under im-
unosuppressive therapy, we cannot discern whether
he decreased production of Th2-associated cytokines by
cells is induced by the chronic GVHD itself or
hether it is related to the accompanying immuno-
uppressive treatment. However, it should be noted
hat our results are in line with those reported by Ochs
t al., [43] who analyzed cytokine production by re-
erse transcription-polymerase chain reaction in skin
amples from patients with chronic GVHD and
howed increased levels of IFN- and TNF-, to-
ether with low amounts of IL-4, IL-5, and IL-10, as
ompared both with patients without chronic GVHD
nd with healthy subjects. Furthermore, Korholz et al.
42] have also recently found similar results, with
ecreased IL-10 and increased TNF- in chronic
VHD patients as determined by enzyme-linked im-
unosorbent assay.
Our comparison of the immune system status in
atients receiving RIC regimens and in those under-
oing conventional myeloablative transplantations
arrants a speciﬁc comment. Although some groups
ave demonstrated an earlier immune recovery in pa-
ients undergoing RIC versus conventional allo-SCT
ransplantations [44-46], in this study there were no
igniﬁcant differences between the 2 groups of pa-
ients in the long term, at least with regard to DCs,
K cells, B cells, and T cells, including cytokine
roduction.In summary, our study shows the existence of
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3everal numeric and functional differences in distinct
ellular compartments of the immune system of pa-
ients undergoing sibling allo-SCT, evaluated more
han 1 year after transplantation, as compared with
heir respective donors. The most relevant numeric
ifferences are related to the distribution of the dis-
inct subsets of PB DCs, associated with an increased
umber of B cells, a decrease in CD4/CD8 double-
ositive T cells and an inverted CD4/CD8 T-cell
atio in the patient group. In addition, a predomi-
ance of a Th1 pattern of cytokine production with
ecreased secretion of Th2-associated cytokines was
lso observed at the single-cell level. Nevertheless,
ecause this was a descriptive study, the importance of
he changes described in the posttransplantation set-
ing should be further conﬁrmed with larger series of
atients and also by sequential analysis.
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